Browsing NTNU Open by Author "Dolan, Ross D."

Now showing items 1-5 of 5

    • Appetite and dietary intake endpoints in cancer cachexia clinical trials: Systematic Review 2 of the cachexia endpoints series 

      Vagnildhaug, Ola Magne; Balstad, Trude Rakel; Ottestad, Inger; Bye, Asta; Greil, Christine; Arends, Jann; Baracos, Vickie; Brown, Leo R.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie; Fraser, Eilidh; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Kaasa, Stein; McDonald, James; Philips, Iain; Sayers, Judith; Simpson, Melanie Rae; Sousa, Mariana S.; Skipworth, Richard J.E.; Laird, Barry J.A.; Solheim, Tora S (Journal article; Peer reviewed, 2024)
      There is no consensus on the optimal endpoint(s) in cancer cachexia trials. Endpoint variation is an obstacle when comparing interventions and their clinical value. The aim of this systematic review was to summarize and ...

    • Biomarker endpoints in cancer cachexia clinical trials: Systematic Review 5 of the cachexia endpoint series 

      Yule, Michael S.; Thompson, Joshua; Leesahatsawat, Khachonphat; Sousa, Mariana S.; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Dajani, Olav; Fallon, Marie; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; McDonald, James; McGovern, Josh; Roeland, Eric J.; Sayers, Judith; Skipworth, Richard J.E.; Ottestad, Inger; Philips, Iain; Simpson, Melanie Rae; Solheim, Tora S; Vagnildhaug, Ola Magne; McMillan, Donald; Laird, Barry J; Dolan, Ross D. (Journal article; Peer reviewed, 2024)
      Regulatory agencies require evidence that endpoints correlate with clinical benefit before they can be used to approve drugs. Biomarkers are often considered surrogate endpoints. In cancer cachexia trials, the measurement ...

    • Body weight and composition endpoints in cancer cachexia clinical trials: Systematic Review 4 of the cachexia endpoints series 

      Brown, Leo R.; Sousa, Mariana S.; Yule, Michael S.; Baracos, Vickie E.; McMillan, Donald C.; Arends, Jann; Balstad, Trude Rakel; Bye, Asta; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Maddocks, Matthew; McDonald, James; Ottestad, Inger; Phillips, Iain; Sayers, Judith; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Solheim, Tora S; Laird, Barry J; Skipworth, Richard J.E. (Journal article; Peer reviewed, 2024)
      Significant variation exists in the outcomes used in cancer cachexia trials, including measures of body composition, which are often selected as primary or secondary endpoints. To date, there has been no review of the most ...

    • An exploratory study examining the relationship between performance status and systemic inflammation frameworks and cytokine profiles in patients with advanced cancer 

      Dolan, Ross D.; Laird, Barry J.A.; Klepstad, Pål; Kaasa, Stein; Horgan, Paul G.; Paulsen, Ørnulf; McMillan, Donald C. (Peer reviewed; Journal article, 2019)
      The role of cytokines in the systemic inflammatory response (SIR) is now well established. This is in keeping with the role of the SIR in tumorigenesis, malignant spread, and the development of cachexia. However, the ...

    • Quality of life endpoints in cancer cachexia clinical trials: Systematic review 3 of the cachexia endpoints series 

      Hjermstad, Marianne Jensen; Jakobsen, Gunnhild; Arends, Jann; Balstad, Trude Rakel; Brown, Leo R.; Bye, Asta; Coats, Andrew J.S.; Dajani, Olav; Dolan, Ross D.; Fallon, Marie T.; Greil, Christine; Grzyb, Alexandra; Kaasa, Stein; Koteng, Lisa Heide; May, Anne M.; McDonald, James; Ottestad, Inger; Philips, Iain; Roeland, Eric J.; Sayers, Judith; Simpson, Melanie Rae; Skipworth, Richard J.E.; Solheim, Tora S; Sousa, Mariana S.; Vagnildhaug, Ola Magne; Laird, Barry J.A. (Journal article; Peer reviewed, 2024)
      The use of patient-reported outcomes (PROMs) of quality of life (QOL) is common in cachexia trials. Patients' self-report on health, functioning, wellbeing, and perceptions of care, represent important measures of efficacy. ...